Prescription for American Drug Independence Act of 2020

I 116TH CONGRESS 2D SESSION H. R. 6670 To provide for an exploration of strategies to increase domestic manufacturing and diversify the supply chain of critical drugs, and for other purposes. IN THE HOUSE OF REPRESENTATIVES MAY 1, 2020 Ms. ESHOO (for herself and Mrs. BROOKS of Indiana) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for an exploration of strategies to increase domes- tic manufacturing and diversify the supply chain of crit- ical drugs, and for other purposes. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled, 2 SECTION 1. SHORT TITLE. 3 This Act may be cited as the ‘‘Prescription for Amer- 4 ican Drug Independence Act of 2020’’. 5 SEC. 2. NATIONAL ACADEMIES STRATEGIES TO INCREASE 6 DOMESTIC MANUFACTURING OF CRITICAL 7 DRUGS. 8 (a) IN GENERAL.—Not later than 14 days after the 9 date of enactment of this Act, the Secretary of Health and 10 VerDate Sep 11 2014 18:26 May 08, 2020 Jkt 099200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H6670.IH H6670 pamtmann on DSKBC07HB2PROD with BILLS 2 •HR 6670 IH Human Services shall enter into an agreement with the 1 National Academies of Sciences, Engineering, and Medi- 2 cine (referred to in this section as the ‘‘National Acad- 3 emies’’) under which, not later than 90 days after the date 4 of entering into the agreement, the National Academies 5 will— 6 (1) establish a committee of experts who are 7 knowledgeable about drug supply issues, including— 8 (A) sourcing and production of critical 9 drugs; 10 (B) sourcing and production of active 11 pharmaceutical ingredients in critical drugs; 12 (C) the raw materials and other compo- 13 nents for critical drugs; and 14 (D) the public health and national security 15 implications of the current supply chain for 16 critical drugs; 17 (2) convene a public symposium to— 18 (A) analyze the impact of United States 19 dependence on the foreign manufacturing of 20 critical drugs on patient access and care, in- 21 cluding in hospitals and intensive care units; 22 and 23 (B) recommend strategies to end United 24 States dependence on foreign manufacturing to 25 VerDate Sep 11 2014 18:26 May 08, 2020 Jkt 099200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H6670.IH H6670 pamtmann on DSKBC07HB2PROD with BILLS 3 •HR 6670 IH ensure the United States has a diverse and vital 1 supply chain for critical drugs to protect the 2 Nation from natural or hostile occurrences; and 3 (3) submit a report on the symposium’s pro- 4 ceedings to the Congress and publish a summary of 5 such proceedings on the public website of the Na- 6 tional Academies. 7 (b) SYMPOSIUM.—In carrying out the agreement 8 under subsection (a), the National Academies shall consult 9 with— 10 (1) the Department of Health and Human 11 Services, the Department of Homeland Security, the 12 Department of Defense, the Department of Com- 13 merce, the Department of State, the Department of 14 Veterans Affairs, the Department of Justice, and 15 any other Federal agencies as appropriate; and 16 (2) relevant stakeholders, including drug manu- 17 facturers, health care providers, medical professional 18 societies, State-based societies, public health experts, 19 State and local public health departments, State 20 medical boards, patient groups, health care distribu- 21 tors, wholesalers and group purchasing organiza- 22 tions, pharmacists, and other entities with experi- 23 ence in health care and public health, as appro- 24 priate. 25 VerDate Sep 11 2014 18:26 May 08, 2020 Jkt 099200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H6670.IH H6670 pamtmann on DSKBC07HB2PROD with BILLS 4 •HR 6670 IH (c) DEFINITIONS.—For the purposes of this section: 1 (1) The term ‘‘critical drug’’ means a drug that 2 is described in subsection (a) of section 506C of the 3 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 4 356c) (relating to notification of any discontinuance 5 or interruption in the production of life-saving 6 drugs). 7 (2) The term ‘‘drug’’ has the meaning given to 8 such term in section 201 of the Federal Food, Drug, 9 and Cosmetic Act (21 U.S.C. 321). 10 Æ VerDate Sep 11 2014 18:26 May 08, 2020 Jkt 099200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6301 E:\BILLS\H6670.IH H6670 pamtmann on DSKBC07HB2PROD with BILLS